4 Top Biotech Stocks to Buy for 2022 -Breaking
[ad_1]
The growing demand for efficient and viable drugs, vaccines, and treatments for curing chronic diseases and newly emerging coronavirus variants should accelerate the biotech industry’s growth over the long term. It might make sense to consider investing in biotech stocks Regeneron, Biogen, United Therapeutics, Exelixis, and Biogen (NASDAQ) that have great potential. The emergence of coronavirus variations is encouraging companies with COVID-19 product pipelines to improve their research and produce new vaccines.
In addition, FDA and EUA regulatory approvals and increasing investment and government policy support worldwide are all positive signs for the future of the biotech sector. Investor optimism in this space is evident from the First Trust NYSE Arca Biotechnology Index ETF’s (FBT) 2.9% gains over the past month versus the SPDR S&P 500 Trust ETF’s (SPY) negative returns. Global biotechnology is projected to expand at 7.7% CAGR, reaching $741.7 billion in 2026.
The fundamentally sound, but undervalued, biotech stocks Regeneron Pharmacy, Inc., Biogen Inc., United Therapeutics Corporation, and Exelixis, Inc. are worth considering. The growing investments, advanced R&D, and impressive breakthroughs in the industry should enable these companies to profit substantially next year.
Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.
[ad_2]